Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.

Autor: Kutsch N; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany., Pallasch C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany., Tausch E; Department of Internal Medicine III, Ulm University, Ulm, Germany., Böhme V; Oncology Lerchenfeld Clinic, Hamburg, Germany., Ritgen M; Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany., Liersch R; Gemeinschaftspraxis für Hämatologie und Onkologie, Clemenshospital Münster, Düesbergweg, Germany., Wacker A; Department of Internal Medicine I, Klinikum am Steinenberg, Reutlingen, Germany., Jacobs G; Praxis Fuer Onkologie, Saarbrücken, Germany., Trappe RU; Department of Hematology and Oncology, DIAKO Hospital Bremen, Germany., Dreger P; Department of Medicine V, University Hospital Heidelberg, Germany., Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany., Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany., Stilgenbauer S; Department of Internal Medicine III, Ulm University, Ulm, Germany., Zhai S; Gilead Sciences, Inc., Foster City, California, USA., Li B; Gilead Sciences, Inc., Foster City, California, USA., Jürgensmeier JM; Gilead Sciences, Inc., Foster City, California, USA., Rajakumaraswamy N; Gilead Sciences, Inc., Foster City, California, USA., Bhargava P; Gilead Sciences, Inc., Foster City, California, USA., Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany., Eichhorst BF; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
Jazyk: angličtina
Zdroj: HemaSphere [Hemasphere] 2022 Mar 08; Vol. 6 (4), pp. e692. Date of Electronic Publication: 2022 Mar 08 (Print Publication: 2022).
DOI: 10.1097/HS9.0000000000000692
Databáze: MEDLINE